Technical Analysis for ANNX - Annexon, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 4.64 | 4.39% | 0.20 |
Earnings due: May 6
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 4.39% | |
Narrow Range Bar | Range Contraction | 4.39% | |
Wide Bands | Range Expansion | 4.39% | |
Oversold Stochastic | Weakness | 4.39% | |
Lower Bollinger Band Walk | Weakness | 1.98% | |
Inside Day | Range Contraction | 1.98% | |
Wide Bands | Range Expansion | 1.98% | |
Oversold Stochastic | Weakness | 1.98% | |
Lower Bollinger Band Walk | Weakness | 1.64% | |
Wide Bands | Range Expansion | 1.64% |
Alert | Time |
---|---|
2x Volume Pace | about 5 hours ago |
1.5x Volume Pace | about 5 hours ago |
Gapped Up (Full) | about 5 hours ago |
Rose Above Previous Day's High | about 5 hours ago |
Up 5% | about 5 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/06/2024
Annexon, Inc. Description
Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The company’s first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company’s second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that its product candidates are engaging the target at a well-tolerated therapeutic dose in the intended patient tissue.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Immunology Immune System Eye Monoclonal Antibody Antibody Ophthalmic Biomarkers Autoimmunity Platform Technology Degenerative Disease Complement System Neurodegenerative Disorders Intravitreal Administration
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 8.4 |
52 Week Low | 1.57 |
Average Volume | 1,783,549 |
200-Day Moving Average | 3.73 |
50-Day Moving Average | 5.67 |
20-Day Moving Average | 5.89 |
10-Day Moving Average | 5.16 |
Average True Range | 0.53 |
RSI (14) | 32.89 |
ADX | 25.45 |
+DI | 19.42 |
-DI | 26.62 |
Chandelier Exit (Long, 3 ATRs) | 6.80 |
Chandelier Exit (Short, 3 ATRs) | 5.88 |
Upper Bollinger Bands | 7.80 |
Lower Bollinger Band | 3.99 |
Percent B (%b) | 0.12 |
BandWidth | 64.66 |
MACD Line | -0.38 |
MACD Signal Line | -0.14 |
MACD Histogram | -0.2362 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 4.82 | ||||
Resistance 3 (R3) | 4.86 | 4.77 | 4.75 | ||
Resistance 2 (R2) | 4.77 | 4.68 | 4.75 | 4.73 | |
Resistance 1 (R1) | 4.61 | 4.62 | 4.57 | 4.57 | 4.71 |
Pivot Point | 4.52 | 4.52 | 4.50 | 4.50 | 4.52 |
Support 1 (S1) | 4.36 | 4.43 | 4.32 | 4.32 | 4.17 |
Support 2 (S2) | 4.27 | 4.37 | 4.25 | 4.15 | |
Support 3 (S3) | 4.11 | 4.27 | 4.13 | ||
Support 4 (S4) | 4.07 |